Related Experiment Video
Updated: Jul 25, 2025

12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.4K
Frontal variant Alzheimer's disease: A systematic narrative synthesis
Andrea Brown1, Sarah K Salo2, Greg Savage1
1School of Psychological Sciences, Macquarie University, Sydney, Australia.
Summary
Frontal variant Alzheimer's disease (fvAD) shows overlapping symptoms with behavioral variant frontotemporal dementia (bvFTD), making differential diagnosis challenging. Further research is needed to distinguish these conditions based on neuropsychological profiles and diagnostic criteria.
Area of Science:
- Neuroscience
- Neurology
- Cognitive Science
Background:
- Frontal variant Alzheimer's disease (fvAD) is a rare Alzheimer's disease (AD) subtype often misdiagnosed as behavioral variant frontotemporal dementia (bvFTD).
- Existing literature frequently conflates behavioral and executive dysfunction in fvAD, utilizing both AD and bvFTD diagnostic criteria for classification.
- This ambiguity complicates the accurate identification and study of fvAD.
Purpose of the Study:
- To synthesize neuropsychological findings in fvAD cohorts.
- To contextualize these findings within established Alzheimer's disease pathology.
- To identify potential areas for improving differential diagnosis between fvAD and bvFTD.
Main Methods:
- A narrative synthesis approach was employed.
- Literature searches were conducted across EMBASE, PsycINFO, PROQUEST, and MEDLINE databases.
- Studies included required both neuropsychological and biomarker evidence.
Main Results:
- Ten studies comprising 342 fvAD, 178 typical AD, and 250 bvFTD participants were reviewed.
- Areas for further investigation include executive dysfunction severity, symptom onset, and cognitive profile similarities between fvAD and typical AD.
- Distinctive features that may aid differential diagnosis were highlighted.
Conclusions:
- Neuropsychological evidence is currently insufficient to definitively differentiate fvAD and bvFTD cognitive phenotypes.
- Disparate diagnostic criteria used for fvAD cohorts contribute to variability in research findings.
- Distinctive features identified may guide future differential diagnostic research.
Related Concept Videos
Alzheimer's Disease: Overview
530
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
530
Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
Dementia
142
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
142
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K

